<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Quest Diagnostics (DGX): Assessing Valuation Following Launch of Nationwide Pharmacogenomic Test for Precision Medicine — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Quest Diagnostics (DGX): Assessing Valuation Following Launch of Nationwide Pharmacogenomic Test for Precision Medicine</h2>
    <div class="badge">2025-09-08T14:14:29+00:00</div>
    <ul>
      <li>Result: Fair Value of $188.19 (UNDERVALUED) Have a read of the narrative in full and understand what&#x27;s behind the forecasts.</li>
<li>Most Popular Narrative: 2.5% Undervalued The most followed narrative sees Quest Diagnostics trading below its estimated fair value, with analysts projecting modest upside from current levels.</li>
<li>This announcement arrives at a moment when Quest Diagnostics is already showing positive stock momentum, with shares returning 21% over the past year and nearly matching that gain year-to-date.</li>
<li>It offers actionable guidance that could make prescribing both safer and more effective.</li>
<li>This supports long-term earnings power.</li>
<li>Curious about why experts think there is still room for this stock to climb?</li>
<li>Want to discover the underlying numbers and key assumptions driving this price target?</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Quest Diagnostics (DGX): Assessing Valuation Following Launch of Nationwide Pharmacogenomic Test for Precision Medicine\n• Result: Fair Value of $188.19 (UNDERVALUED) Have a read of the narrative in full and understand what&#x27;s behind the forecasts.\n• Most Popular Narrative: 2.5% Undervalued The most followed narrative sees Quest Diagnostics trading below its estimated fair value, with analysts projecting modest upside from current levels.\n• This announcement arrives at a moment when Quest Diagnostics is already showing positive stock momentum, with shares returning 21% over the past year and nearly matching that gain year-to-date.\n• It offers actionable guidance that could make prescribing both safer and more effective.\n• This supports long-term earnings power.\n• Curious about why experts think there is still room for this stock to climb?\n• Want to discover the underlying numbers and key assumptions driving this price target?" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/quest-diagnostics-dgx-assessing-valuation-141429190.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>